Maraviroc reduces viral load in naive patients at 48 weeks.
D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D048588:Benzoxazines / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use*; D003521:Cyclopropanes; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D000077592:Maraviroc; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*; D019562:Viral Load
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003510:Cyclohexanes; D003521:Cyclopropanes; D014230:Triazoles; C098320:efavirenz; D000077592:Maraviroc